Sort
23,748 grants matching “melanoma”
EGFRvIII-targeted Bispecific T cell Engagers for brain tumors
$411,170John H Sampson · Duke University · R01 · FY2013 · NS
Core C: Survey Shared Resource Core
$411,164Jessica Chubak · Kaiser Foundation Research Institute · P01 · FY2021 · CA
DNA Repair, Skin Cancer and Overall Cancer Risk
$411,076Anthony J Alberg · Medical University Of South Carolina · R01 · FY2007 · CA
Regulation of JAK/STAT pathways in the eye
$411,057Charles E Egwuagu · National Eye Institute · Z01 · FY2007 · EY
Contribution of the cutaneous APC network to melanoma progression and therapy.
$411,038Miriam Merad · Icahn School Of Medicine At Mount Sinai · R01 · FY2014 · CA
ATF2 in melanoma development and progression
$411,021Ze'ev A Ronai · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2012 · CA
TLR5 signaling as a conserved mechanism of impaired anti-tumor immunity
$410,973Melanie R Rutkowski · University Of Virginia · R01 · FY2025 · CA
DNA Markers As Surrogates:Melanoma Patient Response
$410,895Dave S B Hoon · Saint John'S Cancer Institute · R33 · FY2008 · CA
UV damage, repair, and mutagenesis
$410,850Gerd P Pfeifer · Beckman Research Institute/City Of Hope · R37 · FY2010 · ES
Studies on the effects of a novel intermittent therapy on intratumoral clonal architecture and resistance
$410,835Piro Lito · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA
Studies on the effects of a novel intermittent therapy on intratumoral clonal architecture and resistance
$410,835Piro Lito · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA
Lipid programs in melanocyte transformation
$410,835Richard Mark White · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA
Studies on the effects of a novel intermittent therapy on intratumoral clonal architecture and resistance
$410,835Piro Lito · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
Lipid programs in melanocyte transformation
$410,835Richard Mark White · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA
Studies on the effects of a novel intermittent therapy on intratumoral clonal architecture and resistance
$410,835Piro Lito · Sloan-Kettering Inst Can Research · R01 · FY2019 · CA
Natural Language Processing Platform for Cancer Surveillance
$410,684Guergana K. Savova · Boston Children'S Hospital · UG3 · FY2020 · CA
Identification and cloning of neoantigen-specific T cells for GBM immunotherapy
$410,675Robert M Prins · University Of California Los Angeles · R01 · FY2019 · CA
Identification and cloning of neoantigen-specific T cells for GBM immunotherapy
$410,675Robert M Prins · University Of California Los Angeles · R01 · FY2020 · CA
Identification and cloning of neoantigen-specific T cells for GBM immunotherapy
$410,675Robert M Prins · University Of California Los Angeles · R01 · FY2021 · CA
High Throughput Isolation of Antigen Specific T-cells for Cancer Therapy
$410,668Udai S Kammula · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Targeting exosomal PDL1 to improve immunotherapy
$410,622Wei Guo · Wistar Institute · P50 · FY2022 · CA
Metabolic reprogramming of Tregs in tumor immunity
$410,606Hongbo Chi · St. Jude Children'S Research Hospital · R01 · FY2017 · CA
Metabolic reprogramming of Tregs in tumor immunity
$410,606Hongbo Chi · St. Jude Children'S Research Hospital · R01 · FY2019 · CA
Metabolic reprogramming of Tregs in tumor immunity
$410,606Hongbo Chi · St. Jude Children'S Research Hospital · R01 · FY2020 · CA
HIV induced anti-cancer HERV immunity in prostate, breast and colon cancers
$410,576Douglas F Nixon · Weill Medical Coll Of Cornell Univ · R01 · FY2018 · CA